The med-tech industry turned in a strong stock market performance for the second year in a row in 2018. That's despite the massive retrenchment this quarter in the broader markets, which have fallen into negative territory after soaring earlier in the year. Pharma and biotech stocks also have been hit hard by drug pricing uncertainty and the downside of a long-time frothy market.